Transforming Growth Factor (TGF)-β Type I Receptor Kinase (ALK5) Inhibitor Alleviates Profibrotic TGF-β1 Responses in Fibroblasts Derived from Peyronie’s Plaque
- 1 October 2010
- journal article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 7 (10) , 3385-3395
Abstract
Introduction Transforming growth factor-β1 (TGF-β1) has been identified as an important fibrogenic cytokine associated with Peyronie's disease (PD). Aim The aim of this study was to study the differential expression of the TGF-β1 and Smad transcription factors in plaque tissue from PD patients and to determine the antifibrotic effect of SKI2162 (SK Chemicals, Seoul, South Korea), a novel small-molecule inhibitor of activin receptor-like kinase 5 (ALK5), a type I receptor of TGF-β, in primary fibroblasts derived from human PD plaque. Methods Plaque tissue was isolated from five PD patients, and tunica albuginea tissue was obtained from four control patients. Plaque tissues from a patient with PD were used for primary fibroblast culture. Fibroblasts were pretreated with SKI2162 (10 µM) and then stimulated with TGF-β1 (10 ng/mL). Main Outcome Measures The plaque or tunica albuginea tissue was stained with Masson's trichrome or antibody to TGF-β1, phospho-Smad2 (P-Smad2), and P-Smad3. Protein was extracted from treated fibroblasts for Western blotting, and the membranes were probed with antibody to P-Smad2/Smad2, P-Smad3/Smad3, plasminogen activator inhibitor-1, fibronectin, collagen I, and collagen IV. We also determined the inhibitory effect of SKI2162 on TGF-β1-induced nuclear translocation of Smad2/3 in fibroblasts. Results The plaque tissue from PD patients showed higher TGF-β1, P-Smad2, and P-Smad3 immunoreactivity than did the tunica albuginea tissue from control patients. SKI2162 not only blocked TGF-β1-induced phosphorylation and nuclear translocation of Smad2 and Smad3, but also inhibited the production of extracellular matrix markers in fibroblasts derived from human PD plaque. Conclusion In light of the pivotal role of TGF-β and Smads in the pathogenesis of PD, pharmacologic inhibition of ALK5 may represent a novel targeted approach to treating PD. Piao S, Choi MJ, Tumurbaatar M, Kim WJ, Jin H-R, Shin SH, Tuvshintur B, Yin GN, Song JS, Kwon M-H, Lee S-J, Han J-Y, Kim S-J, Ryu J-K, and Suh J-K. Transforming growth factor (TGF)-β type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-β1 responses in fibroblasts derived from Peyronie's plaque.Keywords
Funding Information
- Korea Science and Engineering Foundation
- Ministry of Education, Science and Technology
This publication has 26 references indexed in Scilit:
- IN-1130, a Novel Transforming Growth Factor-β Type I Receptor Kinase (Activin Receptor-like Kinase 5) Inhibitor, Promotes Regression of Fibrotic Plaque and Corrects Penile Curvature in a Rat Model of Peyronie’s DiseaseThe Journal of Sexual Medicine, 2009
- Role of Increased Penile Expression of Transforming Growth Factor-β1 and Activation of the Smad Signaling Pathway in Erectile Dysfunction in Streptozotocin-Induced Diabetic RatsThe Journal of Sexual Medicine, 2008
- Repeated intratunical injection of adenovirus expressing transforming growth factor-β1 in a rat induces penile curvature with tunical fibrotic plaque: a useful model for the study of Peyronie’s diseaseInternational Journal of Andrology, 2008
- Surgical Treatment of Peyronie’s Disease: A Critical AnalysisEuropean Urology, 2006
- A Critical Analysis of Nonsurgical Treatment of Peyronie’s DiseaseEuropean Urology, 2006
- Selective inhibition of activin receptor–like kinase 5 signaling blocks profibrotic transforming growth factor β responses in skin fibroblastsArthritis & Rheumatism, 2004
- Expanding the paradigm for plaque development in Peyronie's diseaseInternational Journal Of Impotence Research, 2003
- Peyronie's disease cell culture models: phenotypic, genotypic and functional analysesInternational Journal Of Impotence Research, 2002
- Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-β-induced fibronectin in mesangial cellsBiochemical and Biophysical Research Communications, 2002
- Histological and ultrastructural alterations in an animal model of Peyronie’s diseaseBritish Journal of Urology, 1998